TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01536184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circle of Security (COS)
Description: COS is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. It is based on attachment theory of John Bowlby and Mary Ainsworth and integrates neuroscientific principles of emotional regulation and attachment. The protocol contains both educational and therapeutic components. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour.
Study: NCT04671901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Participants will receive weekly doses of romiplostim, beginning with cycle 4. The initial romiplostim dose will be 10 mcg/kg, and subsequent doses w ill vary based on chemotherapy regimen for a target of platelet count \> 75,000- 200,000/mcL. Participants will continue romiplostim until completion of MAP or D9803, as defined above. Maximum romiplostim dose is 10 mcg/kg. Participants will be followed until 6 months after the last dose of romiplostim.
Study: NCT01928316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizolastine domestic (made in China)
Description: Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizolastine domestic (made in China)
Description: Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizolastine (imported)
Description: Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizolastine (imported)
Description: Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8
Study: NCT03046316

Intervention type: OTHER
Group type: OTHER
Intervention: local consolidative treatment
Description: local consolidative treatment to primary or metastases, which includes surgery, radiotherapy or interventional therapy
Study: NCT02511392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS-1Hz

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS-10 Hz

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Study: NCT00325156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' combined DTPa-IPV/Hib vaccine
Description: 4 intramuscular injections
Study: NCT03518619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PFIcope+EMI
Description: The intervention will be comprised of (1) an initial orientation session where the intervention is introduced, receipt of personalized normative information, motives feedback, and the development of an individual's personalized relapse prevention coping skills messages to be utilized through the course of the intervention; (2) EMA for monitoring of affect, drinking intention, alcohol use, and coping skills use; (3) EMI-tailored text messages sent based on EMA responses: individualized, self-chosen relapse prevention coping skills messages when participants report negative affect and intent to drink.
Study: NCT04136379

Intervention type: DIAGNOSTIC_TEST
Intervention: INR monitoring using a CoaguChek POC device
Description: INR monitoring using a CoaguChek POC device
Study: NCT01472016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-700
Description: ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-700
Description: ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-700
Description: ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-700
Description: ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: 5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cetuximab will be administered by intravenous infusion weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Erlotinib will be taken orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-700
Description: ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
Study: NCT02017795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic asthma action plan (eAAP)
Description: An electronic asthma action plan (eAAP) will be provided to intervention group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: written asthma action plan (WAAP)
Description: A written asthma action plan will be given to control group arm
Study: NCT03089268

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: A colonoscopy will be performed to all individuals.

Intervention type: PROCEDURE
Intervention: Polypectomy or biopsy
Description: All lesions will be removed or biopsied during the procedure

Intervention type: GENETIC
Intervention: Molecular analysis
Description: Molecular analysis will be performed in all colorectal cancers and in those polyps diagnosed with serrated lesion
Study: NCT02062164

Intervention type: PROCEDURE
Intervention: bariatric surgery
Description: The intervention takes place in the clinical care setting. The decision for surgery is made by a multidisciplinary team, according to the international guidelines and the recommendations of the German working group on obesity (AGA, www.a.g.a.de). The choice of procedure is made on an individual basis taking into consideration patient inherent factors as well as the recommendations of the operating center. Operations are conducted at certified bariatric centers according to the policies of the German working group on bariatric surgery (CAADIP), and in the context of a structured preparation and follow-up program. The program is offered by a multidisciplinary team (pediatrician, endocrinologist, surgeon, dietician, psychologist/psychiatrist, social worker) and comprises preparation for and education about the surgery and expected lifestyle changes, as well as a structured, multidisciplinary follow-up plan. Subjects sign a contract agreeing to adhere to the recommended follow-up schedule.

Intervention type: OTHER
Intervention: conservative care
Description: Subjects will be seen by a trained study physician every 6 months. Stuctured health assessments will be conducted, and individual treatment recommendations will be made based on the patients motivation and ability(e.g. inpatient obesity rehab, exercise, dietary or behavioral intervention etc.)
Study: NCT04546139

Intervention type: OTHER
Intervention: footwork
Description: six-point footwork

Intervention type: OTHER
Intervention: footwork
Description: six-point footwork
Study: NCT03024203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation - Executive Training
Description: Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as memory, and problem solving ability.
Study: NCT00712010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein
Description: versus the six other arms
Study: NCT03024203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation - Perceptual Training
Description: Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as attention, and processing speed.
Study: NCT02932774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo syrup once daily before 10:00 AM for 2 weeks
Study: NCT03493763

Intervention type: DIAGNOSTIC_TEST
Intervention: 5hmC profile in plasma cell-free DNA after liver resection
Description: Peripheral blood is drawn every 3 months after liver resection for 5hmC test (Time frame: 2 years or until tumor recurrence).
Study: NCT06159933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Late pronation
Description: According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
Study: NCT02815735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: contact lens
Study: NCT04061226

Intervention type: DEVICE
Intervention: Overnight polysomnography
Description: Overnight polysomnography will be performed in a sleep laboratory (EEG, EOG, EMG, ECG, respiratory movements of the chest and abdomen, oro-nasal airflow, and O2 saturation will be examined

Intervention type: DEVICE
Intervention: Overnight polysomnography
Description: Overnight polysomnography will be performed in a sleep laboratory (EEG, EOG, EMG, ECG, respiratory movements of the chest and abdomen, oro-nasal airflow, and O2 saturation will be examined
Study: NCT01357330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245408 (XL147)
Description: Pharmaceutical form:capsule and tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC1936369B
Description: Pharmaceutical form:capsule Route of administration: oral
Study: NCT02456701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTN3379
Description: IV every 2 weeks
Study: NCT02815735

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: contact lens
Study: NCT03398434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAA868
Description: 3 MAA868 doses, single administration, subcutaneous,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAA868
Description: 3 MAA868 doses, single administration, subcutaneous,
Study: NCT02456701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg po bid
Study: NCT00203060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline Mesylate
Description: tablet, 1 or 2 mg, daily, 58 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet, once daily, 58 weeks
Study: NCT00709059

Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: PegIntron 1.5 ug/kg body weight per week subcutaneously for 48 weeks

Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered based on body weight 800-1200 mg/day (\<65 kg: 800 mg; 65 - 85 kg: 1000 mg; \>85 kg: 1200 mg) orally for 48 weeks
Study: NCT02294136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prep-C
Description: PREP-C is a web-based structured clinical interview that healthcare providers of diverse disciplines can be trained to administer. It provides an assessment of a client's psychosocial readiness to begin HCV treatment and identifies domains of functioning which require tailored intervention to improve treatment readiness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control
Description: Attention Control
Study: NCT03960177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04745962

Intervention type: DEVICE
Intervention: Slimscope
Description: Slimscope thin EBUS endoscope is inserted and used to visualize lung nodules.
Study: NCT03398434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAA868
Description: 3 MAA868 doses, single administration, subcutaneous,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Apixaban 5 mg b.i.d
Study: NCT00762723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trinica Anterior Lumbar Plate System
Description: Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trinica Anterior Lumbar Plate System
Description: Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
Study: NCT00712010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein native
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein native
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein native
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein native
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein native
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein native
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total milk protein native
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total milk protein native
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total milk protein native
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total milk protein native
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total milk protein native
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total milk protein native
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk protein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk protein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk protein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk protein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk protein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk protein
Description: versus the six other arms
Study: NCT00198081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COX-2 Inhibitor 6-8 weeks prior to surgery
Description: 400 mg BID 6-8 weeks prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
Description: 400 mg BID for 6 months prior to follow-up EUS or ERCP
Study: NCT00376571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Comparing treatment of either no side branch treatment versus stenting of main vessel and side branch treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Comparing treatment of either no side branch treatment versus stenting of main vessel and side branch treatment
Study: NCT00525967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone plus Acetaminophen or Placebo
Description: Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone plus Acetaminophen or Placebo
Description: Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
Study: NCT03655093

Intervention type: OTHER
Intervention: Validation of AMSQ questionnaire
Description: Participation in the study will be proposed to any patient meeting the inclusion criteria and consulting a neurologist from the SEP reference center of the University Hospital of Rennes.~The neurologist will explain the purpose of the study to the patient, give him the information form.~Without opposition from the patient, the neurologist will give him the self-questionnaire. The patient will fill it during the consultation. In case of disability to the upper limbs making it impossible to fill the questionnaire by the patient, it will be filled by the neurologist or the patient's companion, according to the answers given by the patient.~While the patient completes the questionnaire, a record of clinical information will be filled in by the neurologist.~No additional act will be performed except the questionnaire, which result will not change the patient's management.
Study: NCT02157649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR Tablet under Fasted conditions
Description: Administration of IR Tablets combination of Codeine Phosphate/Guaifenesin 20mg/400mg every 4 hours for 12 hours total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER Tablet under Fed Conditions
Description: Administration of two ER Tablet combination of Codeine Phosphate/Guaifenesin 30mg/600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER Tablet under Fasted Conditions
Description: Administration of two Codeine Phosphate/Guaifenesin 30mg/600mg ER Tablets under fasted conditions.
Study: NCT02056366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: α-lipoic acid
Description: α-lipoic acid 600mg PO medication,Per day, For 6weeks α-lipoic acid 1200mg PO medication,Per day, For 6weeks
Study: NCT01640379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Enhanced Community Health Nursing
Description: * Text-messaging (twice daily medication reminders w/ positive adherence messages, positive sexual health messages throughout the 30 day treatment period)~* Enhanced community health nursing visit on day 3-5, includes evidence-based STI/HIV prevention component (Sister to Sister Teen)
Study: NCT00533702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B (ramucirumab)
Description: 10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMC-1121B (ramucirumab)
Description: 10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
Study: NCT03884517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8003
Description: Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8003
Description: Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
Study: NCT03358459

Intervention type: OTHER
Intervention: non
Description: non